Literature DB >> 2165069

Stable expression of a secretable deletion mutant of recombinant human thrombomodulin in mammalian cells.

J F Parkinson1, B W Grinnell, R E Moore, J Hoskins, C J Vlahos, N U Bang.   

Abstract

Thrombomodulin is an endothelial cell membrane protein which plays a central regulatory role in the protein C anticoagulant pathway. The human thrombomodulin intronless gene was isolated from a genomic DNA library and used to isolate the coding region. A mammalian expression vector, phd-TMD1, encoding all the extracellular domains of human thrombomodulin but lacking the transmembrane and cytoplasmic domains was constructed. Stable phd-TMD 1 transformants, in both hamster AV12-644 and human 293 cells, expressed functionally active recombinant thrombomodulin as a secreted, soluble product. Soluble thrombomodulin was secreted as two major proteins of 105 kDa and 75 kDa, both of which were purified to homogeneity. The kinetic properties for protein C activation of the two proteins were very different: the Kd for thrombin, Km for protein C, and Ca2+ optima were 3.0 nM, 1.5 microM, and 1-3 mM for the 105-kDa protein and 16 nM, 2.3 microM, and 0.2-0.5 mM for the 75-kDa protein. In clotting and platelet activation assays, the 105-kDa protein was a much more potent anticoagulant than the 75-kDa protein. Both forms of the protein had the amino-terminal sequence Ala19-Pro-Ala-Glu-Pro-Gln. Amino acid composition analysis indicated that both forms of the protein had the same amino acid content which was consistent with the predicted protein comprising residues Ala19 to Ser515. The difference in size appeared to be due to glycosylation as both forms were of similar size following chemical deglycosylation. These studies suggest that (1) secretable thrombomodulin derivatives can be used to study structure-function relationships of the extracellular domains of this important regulatory protein, (2) the extent of glycosylation has profound effects on the kinetic and anticoagulant properties of human thrombomodulin, and (3) soluble recombinant human thrombomodulins may be developed as clinically significant therapeutic anticoagulants.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165069

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

Review 1.  New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Jeffrey I Weitz; John W Eikelboom; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.

Authors:  Shannon M Bates; Jeffrey I Weitz
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

3.  The fifth epidermal growth factor-like domain of thrombomodulin does not have an epidermal growth factor-like disulfide bonding pattern.

Authors:  C E White; M J Hunter; D P Meininger; S Garrod; E A Komives
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

4.  Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.

Authors:  S R Lentz; J E Sadler
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

Review 5.  New anticoagulant drugs.

Authors:  J I Weitz
Journal:  J Thromb Thrombolysis       Date:  2001-09       Impact factor: 2.300

6.  Thrombin inhibition by cyclic peptides from thrombomodulin.

Authors:  J C Lougheed; C L Bowman; D P Meininger; E A Komives
Journal:  Protein Sci       Date:  1995-04       Impact factor: 6.725

7.  Bio-inspired liposomal thrombomodulin conjugate through bio-orthogonal chemistry.

Authors:  Hailong Zhang; Jacob Weingart; Rui Jiang; Jianhao Peng; Qingyu Wu; Xue-Long Sun
Journal:  Bioconjug Chem       Date:  2013-03-15       Impact factor: 4.774

8.  Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation.

Authors:  C B Glaser; J Morser; J H Clarke; E Blasko; K McLean; I Kuhn; R J Chang; J H Lin; L Vilander; W H Andrews; D R Light
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

9.  Identification of the predominant glycosaminoglycan-attachment site in soluble recombinant human thrombomodulin: potential regulation of functionality by glycosyltransferase competition for serine474.

Authors:  B Gerlitz; T Hassell; C J Vlahos; J F Parkinson; N U Bang; B W Grinnell
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

10.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.